Salesforce Stock Has Surged as AI and Anthropic Bets Pay Off, But Technical Risks Remain
Salesforce stock has surged to its highest level in months as its AI and Anthropic bets paid off, but its technical risks remain
Stocks · News reference
CNBC Halftime Report Final Trades: Pfizer, Nvidia, Take-Two Interactive Software, Cheniere Energy
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bloom Energy Stock Faces Key Risks as Growth Fuels S&P 500 Index Inclusion
Bloom Energy jumped to a crucial resistance level as its revenue growth fueled its upcoming inclusion to the S&P 500 Index.
Jensen Huang's Net Worth Up $36 Billion as Nvidia Stock Eyes Surge to Record High
The ongoing Nvidia stock surge has pushed Jensen Huang's net worth by over $48 billion and is the eighth-richest man in the world.
David Sacks Says AI Debate Is Shifting From ‘Doomers’ to Open vs. Closed Models
David Sacks says AI politics is shifting from speed versus caution to open, decentralized systems versus centralized control by major firms.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.